Note: Hydroxychloroquinone has recently been approved by DCGI for the treatment of T2DM as third-line therapy; SGLT2 inhibitors are recommended in patients with high CV risk. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.